博安生物(06955.HK)度拉糖(月太)注射液博優平在中國獲批上市
博安生物(06955.HK)公布,公司自主開發的博優平(度拉糖(月太)注射液)已獲得國家藥品監督管理局的上市批准,用於成人2型糖尿病患者的血糖控制。
度拉糖(月太)是一種長效胰高血糖素樣(月太)-1(GLP-1)受體激動劑,每周給藥一次。度拉糖(月太)可改善胰島β細胞的功能,穩定、有效地降低血糖及糖化血紅蛋白(HbA1c)水平。此外,度拉糖(月太)亦具備多重臨床獲益,包括可減少主要心血管不良事件,減輕體重,對腎臟具有保護作用,且低血糖發生率低,胃腸道不良反應低。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.